In our tumor-adjusted model, NKSCC showed an increased risk with the presence of SMARCB1 mosaic expression (HR = 2.96, 95% CI = 9.53–17.09, p 0.05), with a median survival of 13.31 months, compared to 25.0 months for intact expression (Figure 4A). This evidence concerns the gene SMARCB1 and neoplasm.